CDC urges anti-HIV pill for people at high risk of infection

May 15, 2014 by E.j. Mundell, Healthday Reporter
CDC urges anti-HIV pill for people at high risk of infection
Targeted groups include people with an infected partner or those who don't practice safe sex.

(HealthDay)—People deemed to be at high risk for contracting HIV, the virus that causes AIDS, should take anti-HIV medicines that seem to cut transmission risk, the U.S. Centers for Disease Control and Prevention announced Wednesday.

If used consistently, this approach, called pre-exposure prophylaxis (PrEP), has been shown to reduce HIV infection rates in prior studies by as much as 90 percent, the CDC noted.

"HIV infection is preventable, yet every year we see some 50,000 new HIV infections in the United States," CDC director Dr. Tom Frieden said in a news release from the agency. "PrEP, used along with other prevention strategies, has the potential to help at-risk individuals protect themselves and reduce new HIV infections in the United States."

The new guidelines are tied to the 2012 approval by the U.S. Food and Drug Administration of a combo drug called Truvada for use as PrEP, along with practices.

"While a vaccine or cure may one day end the HIV epidemic, PrEP is a powerful tool that has the potential to alter the course of the U.S. HIV epidemic today," Dr. Jonathan Mermin, director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in the news release.

The new guidelines say that the use of the PrEP regimen should be considered by the following groups:

  • Anyone involved in an ongoing relationship with a person who is already infected with HIV;
  • Any gay or bisexual man who has had sex without a condom or who has been diagnosed with a sexually transmitted infection within the past six months, and is not in a mutually monogamous relationship with someone who recently tested HIV-negative;
  • A heterosexual person who does not always use condoms when having sex with people who might be at high risk for HIV (injection drug users or bisexual male partners whose HIV status is unknown) and is also not involved with an HIV-negative person in a mutually monogamous relationship;
  • Anyone who has abused injected, illicit drugs over the past six months, shared needles or other equipment tied to injected drug abuse, or been in a drug abuse treatment program.

The CDC is offering PrEP providers with support to help make sure that people on the regimen adhere to it as closely as possible—always an issue, the agency said. Pills need to be taken regularly or the level of protection from PrEP drops dramatically, the CDC noted.

That's why safe sex practices— condoms, especially—remain important.

One expert in the field said that preventing HIV will always take more than a pill.

"We applaud the CDC for acknowledging the effectiveness of PrEP to reduce the risk of HIV infection among those individuals at greatest risk of HIV transmission," said Dr. Michael Mullen, professor of medicine and infectious diseases at the Icahn School of Medicine at Mount Sinai, in New York City.

"However, it must be emphasized that PrEP cannot and should not be used alone as prophylaxis against HIV infection—rather, PrEP must be used in combination with other proven preventive measures, including practicing safe sex, being tested regularly for STDs, and knowing your and your partner's HIV status," he said.

Dr. Dawn Smith is the epidemiologist in CDC's Division of HIV/AIDS Prevention who led the development of the guidelines. She stressed that, "individuals will have to decide with their doctor if PrEP is right for them, but for some, this may offer a much-needed strategy to help protect themselves from HIV infection."

But the strategy will require teamwork, she added.

"PrEP is a new approach to HIV prevention that requires continuing collaboration between patients and providers, as effectiveness requires adherence to daily medication and regular medical visits for monitoring, counseling and testing," Smith said.

The new guidelines were published May 14 in the CDC journal Morbidity and Mortality Weekly Report.

Explore further: HIV answers raise new ethical questions

More information: There's more on preventing HIV infection at the U.S> National Institutes of Health.

Related Stories

HIV answers raise new ethical questions

July 31, 2013
The Food and Drug Administration's approval last year of the drug Truvada for prevention of HIV infection was a milestone in the fight against HIV/AIDS, but experts are cautioning that it is only the beginning of new ethical ...

US reports rare case of woman-to-woman HIV transmission (Update)

March 13, 2014
A rare case of suspected HIV transmission from one woman to another was reported Thursday by US health authorities.

UNAIDS welcomes US approval of drug to stop HIV

July 17, 2012
The UN agency tasked with fighting AIDS on Tuesday welcomed the decision by the United States to allow the use of an HIV prevention pill for the first time.

High-risk heterosexuals should take HIV prevention pill, too

August 10, 2012
(HealthDay) -- Doctors should consider prescribing the HIV prevention pill Truvada to their heterosexual patients who are at high risk for the virus, not just high-risk gay and bisexual men, experts from the U.S. Centers ...

Effectiveness of HIV pre-exposure prophylaxis in Peru

October 9, 2012
In this week's PLOS Medicine, Anna Borquez from Imperial College London and an international group of authors developed a mathematical model representing the HIV epidemic among men who have sex with men (MSM) and transwomen ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.